Leukemia, Myelogenous, Chronic, BCR-ABL Positive: all 982 studies

Page 3 of 10. Open to participants first (109), then studies with results posted, then the rest; newest registration first within each.

• A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01667133Phase 1/2Results posted
• Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to ImatinibCompletedNCT01660906Phase 4Results posted
• Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T CellCompletedNCT01660607Phase 1/2Results posted
• Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)TerminatedNCT01650805Phase 3Results posted
• T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic TransplantTerminatedNCT01621477Phase 2Results posted
• Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TARCompletedNCT01611298Not applicableResults posted
• Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to ImatinibCompletedNCT01593254Phase 2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)TerminatedNCT01570868Phase 2Results posted
• Rasburicase and Allopurinol in Treating Patients With Hematologic MalignanciesTerminatedNCT01564277Phase 2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01527045Phase 2Results posted
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciesCompletedNCT01499147Not applicableResults posted
• An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)TerminatedNCT01498445Phase 1/2Results posted
• Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
• Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT01445080Phase 1/2Results posted
• Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase TherapyCompletedNCT01428635Phase 2/3Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• Pegasys in Patients With Chronic Myeloid Leukemia (CML)TerminatedNCT01392170Phase 2Results posted
• Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATGCompletedNCT01390402Phase 2Results posted
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body IrradiationTerminatedNCT01366612Phase 3Results posted
• Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative DonorCompletedNCT01350245Phase 2Results posted
• Phase I Study of OPB-51602 in Patients With Hematologic MalignanciesCompletedNCT01344876Phase 1Results posted
• Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow TransplantationCompletedNCT01338987Phase 2Results posted
• Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT01326728Results posted
• Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantCompletedNCT01305200Phase 3Results posted
• Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs VidazaCompletedNCT01290302Phase 1Results posted
• Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP PatientsCompletedNCT01275196Phase 3Results posted
• Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT01274351Phase 2Results posted
• Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia PatientsCompletedNCT01254188Phase 3Results posted
• Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantCompletedNCT01251575Phase 2Results posted
• Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic CancerCompletedNCT01233921Not applicableResults posted
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell TransplantCompletedNCT01231412Phase 3Results posted
• CMR Rate of Newly Diagnosed CML-CP Patients Treated With NilotinibCompletedNCT01227577Phase 4Results posted
• Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01207440Phase 2Results posted
• Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic MalignanciesCompletedNCT01188798Phase 3Results posted
• Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia PatientsTerminatedNCT01169753Not applicableResults posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic CancersTerminatedNCT01135329Phase 2Results posted
• Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma ConcentrationsTerminatedNCT01131325Phase 4Results posted
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
• A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)CompletedNCT01077544Phase 1Results posted
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01076270Not applicableResults posted
• Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord UnitTerminatedNCT01050946Phase 2Results posted
• Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cellsTerminatedNCT01050764Phase 1/2Results posted
• Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic CancerTerminatedNCT01044745Phase 2Results posted
• Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal ResponseCompletedNCT01043874Phase 4Results posted
• A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic MalignanciesCompletedNCT01036009Phase 2Results posted
• Rollover Study of BMS-354825 in Patients With CML and Ph+ALLCompletedNCT01030718Phase 1/2Results posted
• Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic MalignanciesCompletedNCT00988013Not applicableResults posted
• Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00982488Phase 2Results posted
• An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib TreatmentCompletedNCT00980018Phase 4Results posted
• Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic StudyCompletedNCT00978731Phase 1Results posted
• Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood CancerCompletedNCT00975975Phase 2Results posted
• T-cell Depleted Alternative Donor TransplantationTerminatedNCT00968864Phase 2Results posted
• Ondansetron Versus Aprepitant Plus Ondansetron for EmesisCompletedNCT00954941Phase 2Results posted
• Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the BloodCompletedNCT00923910Phase 1/2Results posted
• Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)TerminatedNCT00907517Phase 1Results posted
• Sitagliptin Umbilical Cord Blood Transplant StudyCompletedNCT00862719Phase 2Results posted
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic LeukemiaCompletedNCT00860574Phase 2Results posted
• Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)TerminatedNCT00860535Phase 1Results posted
• Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell TransplantationCompletedNCT00859586Not applicableResults posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)CompletedNCT00813124Phase 2Results posted
• Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive LeukemiasCompletedNCT00811070Phase 2Results posted
• Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to ImatinibCompletedNCT00802841Phase 3Results posted
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood TransplantCompletedNCT00796068Phase 2Results posted
• Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2Results posted
• Bendamustine in Acute Leukemia and MDSTerminatedNCT00790855Phase 1/2Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerCompletedNCT00789776Phase 1/2Results posted
• Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)CompletedNCT00760877Phase 3Results posted
• Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.CompletedNCT00739141Phase 2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerCompletedNCT00723099Phase 2Results posted
• Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseCompletedNCT00719888Phase 2Results posted
• Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCTCompletedNCT00709592Phase 2Results posted
• Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CMLCompletedNCT00702403Phase 1/2Results posted
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00683046Phase 2Results posted
• INCB018424 in Patients With Advanced Hematologic MalignanciesCompletedNCT00674479Phase 2Results posted
• Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to ImatinibTerminatedNCT00644878Phase 2Results posted
• Clofarabine and Non-Myeloablative Allogeneic Hematopoietic TransplantationTerminatedNCT00626626Phase 1/2Results posted
• In-Vivo Activated T-Cell Depletion to Prevent GVHDTerminatedNCT00594308Not applicableResults posted
• Phase 2 Haplotype Mismatched HSCT in Patients With Hematological MalignanciesTerminatedNCT00593554Phase 2Results posted
• Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)TerminatedNCT00579111Phase 1/2Results posted
• Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CMLCompletedNCT00574873Phase 3Results posted
• Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid LeukemiaTerminatedNCT00573378Phase 2Results posted
• Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell TransplantCompletedNCT00571662Phase 2Results posted
• Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological MalignanciesCompletedNCT00566696Phase 2Results posted
• Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid CancerTerminatedNCT00540995Phase 1/2Results posted
• Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHDCompletedNCT00539695Phase 2Results posted
• Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood CancersTerminatedNCT00539656Phase 1/2Results posted
• Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)TerminatedNCT00519090Phase 3Results posted
• Aflibercept in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00509249Phase 2Results posted
• Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) PatientsCompletedNCT00493181Phase 2Results posted
• Peptide Vaccinations to Treat Patients With Low-Risk Myeloid CancersCompletedNCT00488592Phase 2Results posted
• A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid LeukemiaCompletedNCT00482703Phase 1/2Results posted
• A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaCompletedNCT00481247Phase 3Results posted
• A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT00471497Phase 3Results posted
• Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid LeukemiaCompletedNCT00469014Phase 2Results posted
• Stem Cell Transplantation for Patients With Cancers of the BloodCompletedNCT00467961Phase 2Results posted
• Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous LeukemiaCompletedNCT00466726Phase 2Results posted

← Leukemia, Myelogenous, Chronic, BCR-ABL Positive overview